Jax DiEugenio

Fedratinib showed early improvements in platelet count in patients with myelofibrosis.

UF-Kure19, a rapidly manufactured CAR T-cell therapy, generated an 80% complete response rate in relapsed/refractory non-Hodgkin lymphoma.

The CHMP has recommended approval for durvalumab in limited-stage small cell lung cancer following platinum-based chemoradiation.

Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

A retrospective analysis showed a high proportion of endometrial cancer samples expressed FRα or B7-H4.

China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.

Results from SWOG S1815 showed no survival benefit for nab-paclitaxel plus gemcitabine and cisplatin in advanced biliary tract cancer.

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab with chemotherapy for advanced gastric or GEJ adenocarcinoma.

Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

GCC19CART generated responses in refractory metastatic colorectal cancer.

NAPOLI 3 post hoc findings show dose reductions of liposomal irinotecan or oxaliplatin did not worsen OS in pancreatic ductal adenocarcinoma.

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

The FDA has granted 510(k) clearance for the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an assay designed to assist pathologists in diagnosing B-cell lymphoma

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.

Roxana S. Dronca, MD, discusses the FDA approval of subcutaneous nivolumab across solid tumor indications.

The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.

The FDA has granted orphan drug designation for the treatment of patients with hepatocellular carcinoma.

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.

Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.

Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.

Roy S. Herbst, MD, explores evolving chemoimmunotherapy strategies for early-stage NSCLC that does not harbor actionable mutations.

R. Lor Randall, MD, FACS, discusses advancements in preclinical research identifying therapeutic vulnerabilities in soft tissue sarcomas.

DETECT V trial data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.